Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial
The combination of lefitolimod (administered subcutaneously or intratumorally) and ipilimumab was safe and well tolerated but demonstrated modest antitumor activity in patients with advanced cancers. <b>ClinicalTrials.gov ID: NCT02668770</b>.
Authors
- Daniel D. Karp (ORCID: https://orcid.org/0000-0002-5017-328X)
- David S. Hong (ORCID: https://orcid.org/0000-0001-8721-1609)
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- Ly M. Nguyen (ORCID: https://orcid.org/0009-0000-8919-7097)
- Vivek Subbiah (ORCID: https://orcid.org/0000-0002-6064-6837)
- Apostolia Maria Tsimberidou (ORCID: https://orcid.org/0000-0003-2713-233X)
- Siqing Fu (ORCID: https://orcid.org/0000-0002-1933-0419)
- Aung Naing
- Michael A. Curran (ORCID: https://orcid.org/0000-0003-4996-7207)
- Casey R. Ager (ORCID: https://orcid.org/0000-0003-0507-700X)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Mohamed A. Gouda (ORCID: https://orcid.org/0000-0003-4829-6739)
- Amadeo B. Biter (ORCID: https://orcid.org/0000-0001-8794-4394)
- Matthew J. Reilley (ORCID: https://orcid.org/0000-0002-4725-0459)
- Priya Bhosale (ORCID: https://orcid.org/0000-0003-4014-4941)
- Mirella Nardo (ORCID: https://orcid.org/0000-0002-9396-7864)
- Coline A. Couillault
- JoAnn Lim (ORCID: https://orcid.org/0000-0001-7983-3264)
- Stacie A. Bean (ORCID: https://orcid.org/0000-0002-9432-2945)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Journal of Immunotherapy and Precision Oncology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.36401/jipo-24-17
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- U.S. Department of Defense
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Cancer Prevention and Research Institute of Texas
- Gilead Sciences
- American Society of Clinical Oncology
- Oregon Health and Science University
- Golfers Against Cancer
- Karyopharm Therapeutics
- Helsinn
- BioMarin Pharmaceutical
- Regeneron Pharmaceuticals
- Exelixis
- Jazz Pharmaceuticals
- Novocure
- National Comprehensive Cancer Network
- Astex Pharmaceuticals
- Parker Institute for Cancer Immunotherapy
- Five Prime Therapeutics
- MEI Pharma
- Millendo Therapeutics
- BeiGene
- Incyte
- Calithera Biosciences
- Innovent Biologics
- Carrick Therapeutics
- Ribon Therapeutics
- Cardinal Health
- Aminex Therapeutics
- F-star Therapeutics
- Puma Biotechnology
- Silverback Therapeutics
- MacroGenics
- Glenmark Pharmaceuticals
- Seagen
- Natera
- Cancer Research UK
- Institut Gustave-Roussy
- Servier
- Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung
- PharmaMar
- Ipsen
- Mereo BioPharma
- National Institutes of Health
- Genentech
- EMD Serono
- University of Texas MD Anderson Cancer Center
- Chugai Pharmaceutical
- Takeda Oncology
- Ignyta
- Loxo Oncology
- Principia Biopharma
- National Cancer Institute
- Daiichi Sankyo Europe